naltrexone targets OPRM1

Subject: naltrexone
Relation: targets
Object: OPRM1
p-value: —

Evidence from: primary | all sources

Evidence (7 sources)

Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol. (2020) PMID:32561311 primary

opioid antagonist naltrexone ... found no effect

confidence: 0.80

Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. (2018) PMID:30167705 cited

Naltrexone is a non-selective antagonist of mu, kappa, and delta opioid receptors

confidence: 0.98

Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. (2017) PMID:28134463 cited

Variations in the μ-opioid receptor (OPRM1) gene and response to NTX are among the most commonly investigated pharmacogenetic effects in research on AUDs.

confidence: 0.90

Pharmacogenetics of OPRM1. (2014) PMID:24201053 cited

Naltrexone, a MOR antagonist

confidence: 0.96

Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. (2012) PMID:22954510 cited

naltrexone dose (50mg) blocked nearly all (about 94%) of mu opioid receptors

confidence: 0.96

Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. (2012) PMID:22954510 cited

naltrexone has highest binding affinity for mu‑opioid receptors encoded by the OPRM1 gene

confidence: 0.90

Pharmacological treatment of cannabis dependence. (2011) PMID:21524266 cited

Naltrexone acts as an antagonist of the mu‑opioid receptor (mOR), the protein product of OPRM1.

confidence: 0.90